Updated: November 7, 2017
James E. (Jim) Audia, PhD joined the CBC as Executive Director on August 1, 2017. Jim has had a long and distinguished career in the pharmaceutical industry. After earning a PhD from the University of South Carolina and completing a postdoctoral fellowship at Yale University, Jim joined Eli Lilly in 1987 where he served in a variety of research and management positions for 24 years, playing a central role in Lilly’s R&D portfolio governance for more than a decade. Jim retired in 2010 as a Distinguished Lilly Scholar, the highest rung of the scientific career ladder at Lilly and at that time was among the most prolific inventors in the company’s history, with more than 90 issued US patents (now exceeding 100). In 2011 he joined the Cambridge-based Constellation Pharmaceuticals. Under Jim’s leadership, Constellation translated its basic science expertise in transcriptional control into a robust portfolio of candidate drugs to treat a variety of cancers. Jim now serves on Constellation’s Board of Directors and as a special scientific advisor. Additionally, Jim remains a member of the Chemistry Advisory Board of SAGE Therapeutics, and the Scientific Advisory Boards of the Tau Consortium of the Rainwater Charitable Foundation, and Ribon Therapeutics. More recently Jim has joined the Executive Advisory Board for UICentre and the NewCures Advisory Board.
Jim succeeds Kathryn C. (Katie) Stallcup, PhD, who retired in September 2017. Katie has served as Executive Director since the CBC’s launch in 2006.